Novo Nordisk
Long-acting GLP-1 receptor agonist (acylated peptide). SUSTAIN and STEP programs established glycemic control, weight loss, and SELECT CV outcomes in obesity. 대표 임상 효능: ORR 14.9% (STEP 1 / SELECT).
GLP-1 receptor
Type 2 diabetes, chronic weight management, CV risk reduction (T2D)
Global
Approved
GLP-1 receptor agonist (peptide)
effects
linker
Acylation + amino acid substitutions for albumin binding / DPP-4 resistance
Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus)
T2D; obesity BMI ≥30 or ≥27 with comorbidity
1L–2L after metformin (T2D); chronic weight management
SC weekly or oral daily
q1w SC (titrated) or oral daily
HbA1c ↓1.5–2%; weight ↓15% (STEP)
GI events (nausea), gallbladder; thyroid C-cell tumor boxed warning
GLP-1 class anchor vs tirzepatide dual agonist
GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety
macrophage activation
apoptosis, and, in some studies, ferroptosis
HbA1c, body weight, waist circumference
GI intolerance leading to discontinuation; plateau after dose titration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
FDA approval (T2D Ozempic)
APPROVAL · 2017년 12월
Wegovy obesity label
APPROVAL · 2021년 6월
Novo Nordisk
Long-acting GLP-1 receptor agonist (acylated peptide). SUSTAIN and STEP programs established glycemic control, weight loss, and SELECT CV outcomes in obesity. 대표 임상 효능: ORR 14.9% (STEP 1 / SELECT).
GLP-1 receptor
Type 2 diabetes, chronic weight management, CV risk reduction (T2D)
Global
Approved
GLP-1 receptor agonist (peptide)
effects
linker
Acylation + amino acid substitutions for albumin binding / DPP-4 resistance
Weekly SC (Ozempic/Wegovy) and oral form (Rybelsus)
T2D; obesity BMI ≥30 or ≥27 with comorbidity
1L–2L after metformin (T2D); chronic weight management
SC weekly or oral daily
q1w SC (titrated) or oral daily
HbA1c ↓1.5–2%; weight ↓15% (STEP)
GI events (nausea), gallbladder; thyroid C-cell tumor boxed warning
GLP-1 class anchor vs tirzepatide dual agonist
GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety
macrophage activation
apoptosis, and, in some studies, ferroptosis
HbA1c, body weight, waist circumference
GI intolerance leading to discontinuation; plateau after dose titration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
FDA approval (T2D Ozempic)
APPROVAL · 2017년 12월
Wegovy obesity label
APPROVAL · 2021년 6월